- Home
- AMWD vs XERS Comparison
AMWD vs XERS Comparison
Compare AMWD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMWD | XERS |
|---|---|---|
| Founded | 1980 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.8M | 965.6M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMWD | XERS |
|---|---|---|
| Price | $37.56 | $5.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $63.50 | $10.83 |
| AVG Volume (30 Days) | 197.2K | ★ 2.0M |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,709,585,000.00 | $49,590,000.00 |
| Revenue This Year | N/A | $28.65 |
| Revenue Next Year | N/A | $18.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $37.56 | $3.81 |
| 52 Week High | $72.16 | $10.08 |
Technical Indicators
Market Signals| Indicator | AMWD | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 20.25 | 28.93 |
| Support Level | N/A | $4.87 |
| Resistance Level | $58.01 | $5.49 |
| Average True Range (ATR) | 1.86 | 0.35 |
| MACD | -0.57 | -0.03 |
| Stochastic Oscillator | 0.64 | 2.28 |
Price Performance
Historical ComparisonAbout AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.